Dupixent
Product Images NDC 0024-5911

Product Visual Gallery

This gallery contains 100 technical images submitted to the FDA as part of the official labeling for Dupixent (NDC 0024-5911). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (Dupixent 01)

A line graph comparing the proportion of subjects (%) over 16 weeks between DUPIXENT 300 mg administered every two weeks (Q2W) and placebo groups. The graph shows a steadily increasing response in the DUPIXENT group reaching 40.8% at week 16, versus 12.3% in the placebo group.*

FDA Label Image

Figure (Dupixent 02)

A line graph comparing the proportion of subjects (%) over time (weeks) between Dupixent 300 mg Q2W (225 subjects) and placebo (221 subjects). The graph shows higher proportions for Dupixent, reaching 36.0% at 16 weeks, versus 9.5% for placebo.*

FDA Label Image

Figure (Dupixent 03)

A line graph comparing the proportion of subjects (%) over 16 weeks between two groups: Dupixent (Dupilumab) 200 mg or 300 mg every two weeks and placebo. The Dupixent group shows an increase to 36.6%, while the placebo group remains near 4.8%. The graph illustrates treatment response over time in a study with 82 subjects on Dupixent and 85 on placebo.*

FDA Label Image

Figure (Dupixent 04)

A bar chart showing the proportion of subjects (%) by weight group treated with Dupilumab plus TCS versus placebo plus TCS. For subjects under 30 kg, Dupilumab 300 mg every 4 weeks shows a 54.1% response compared to 11.7% for placebo. For subjects 30 kg or greater, Dupilumab 200 mg every 2 weeks shows a 61.4% response compared to 12.9% for placebo.*

FDA Label Image

Figure (Dupixent 05)

A forest plot chart showing the rate ratio of Dupixent 200 mg and 300 mg administered every two weeks versus placebo across baseline blood eosinophil groups. The chart compares overall and subgroup rate ratios with 95% confidence intervals, indicating Dupixent's relative effect compared to placebo.*

FDA Label Image

Figure (Dupixent 06)

A forest plot showing rate ratios comparing Dupixent 300 mg Q2W and 200 mg Q2W to placebo across different baseline FeNO groups. The graph presents overall results and subgroups with FeNO levels ≥25 ppb and <25 ppb, including sample sizes and 95% confidence intervals indicating efficacy results of Dupixent versus placebo.*

FDA Label Image

Figure (Dupixent 07)

A line graph showing the probability of event (%) over time (weeks) comparing Dupixent 300 mg and 200 mg administered every two weeks (Q2W) versus placebo groups. The graph includes data points and error bars with numerical risk counts at various weeks for each treatment group.*

FDA Label Image

Figure (Dupixent 08)

A chart showing least squares (LS) mean difference with 95% confidence intervals comparing Dupixent 300 mg and 200 mg every two weeks versus placebo. The horizontal axis shows LS mean difference from -0.25 to 0.5, with a vertical line at zero separating placebo better and Dupixent better. Five groups are shown by baseline blood eosinophil counts (cells/mcL): Overall, ≥500, ≥300 - <500, ≥150 - <300, and <150, with sample sizes and LS mean difference values presented for each group. Dupixent 300 mg doses are represented by squares and Dupixent 200 mg doses by circles.*

FDA Label Image

Figure (Dupixent 09)

A forest plot showing LS mean differences with 95% confidence intervals comparing Dupixent 300 mg and 200 mg every 2 weeks versus placebo across overall, baseline FeNO ≥25, and baseline FeNO <25 groups. The horizontal axis indicates LS mean difference favoring placebo on the left and Dupixent on the right. Numeric group sizes and confidence intervals accompany each comparison.*

FDA Label Image

Figure (Dupixent 10)

A line graph showing least squares mean change in liters (L) with standard error over 52 weeks for Dupixent at 200 mg and 300 mg doses administered every 2 weeks (Q2W) compared to placebo groups. The y-axis represents change in liters, and the x-axis represents time in weeks, illustrating sustained improvements for both Dupixent doses versus placebo over one year.*

FDA Label Image

Dupixent 100

An instructional illustration showing a hand holding a prefilled syringe inside an open box with compartments for other contents. The image is likely related to preparation or administration of a prefilled syringe product, such as Dupixent, but does not contain text or dosage details.*

FDA Label Image

Dupixent 101

An instructional diagram showing items for administration of Dupixent pre-filled syringe. It depicts a pre-filled syringe and lists necessary supplies: 1 alcohol wipe, 1 cotton ball or gauze, and a sharps disposal container.*

FDA Label Image

Dupixent 102

FDA Label Image

Dupixent 103

An instructional diagram showing a Dupixent injection device or syringe with a focus on the label area. The diagram highlights where to find the lot number and expiration date on the device, including arrows pointing to these label details for user reference.*

FDA Label Image

Dupixent 104

FDA Label Image

Dupixent 105

An instructional diagram showing a Dupixent prefilled syringe with a labeled viewing window. The image points to the window area where the lot number and expiration date are displayed on the syringe barrel for verification before use.*

FDA Label Image

Dupixent 106

FDA Label Image

Dupixent 107

FDA Label Image

Dupixent 108

FDA Label Image

Dupixent 109

An instructional illustration showing a syringe with a timer indicating a 30-minute period. The image likely depicts timing guidance related to the use of the syringe.*

FDA Label Image

Figure (Dupixent 11)

Line graph showing the least squares mean change in pEFV over 52 weeks comparing Dupixent (N=175) to placebo (N=84). The x-axis represents weeks from 0 to 52 and the y-axis indicates change values with error bars representing standard error. Dupixent shows a higher increase in pEFV over time, reaching approximately 12.43, while placebo peaks around 4.08.*

FDA Label Image

Dupixent 110

FDA Label Image

Dupixent 111

An illustration showing body areas for Dupixent injection by caregiver only, highlighting the outer upper arms, abdomen (avoiding the navel), and front of the thighs as injection sites.*

FDA Label Image

Dupixent 112

FDA Label Image

Dupixent 113

An illustration showing a hand applying a small square patch to the lower abdomen area, likely demonstrating the placement of a transdermal patch or similar topical drug delivery system.*

FDA Label Image

Dupixent 114

FDA Label Image

Dupixent 115

FDA Label Image

Dupixent 116

An instructional illustration showing two hands preparing a syringe, with arrows indicating the removal of a cap or protective cover before use. The image likely relates to administration guidance for Dupixent injectable product.*

FDA Label Image

Dupixent 117

An instructional illustration showing a hand pinching the skin on the lower abdomen, likely demonstrating a site for subcutaneous injection.*

FDA Label Image

Dupixent 118

Instructional illustration showing how to hold and inject Dupixent at a 45-degree angle, demonstrating the correct technique for administering the injectable medication.*

FDA Label Image

Dupixent 119

An instructional illustration showing a hand holding and preparing a Dupixent pre-filled syringe for injection at the abdomen area. The image depicts proper hand placement and site selection for subcutaneous injection of Dupixent, a medication by Sanofi-Aventis U.S. LLC available in strengths 200 mg/1.14 mL and 300 mg/2 mL.*

FDA Label Image

Dupixent 11a

A line graph comparing the least squares mean change with standard error over 52 weeks between Dupixent 300 mg administered every two weeks and placebo. The vertical axis represents LS mean change +/- SE, and the horizontal axis displays time in weeks. Dupixent shows a notable decreasing trend over time, while placebo remains near zero.*

FDA Label Image

Dupixent 11b

A line graph comparing LS mean change over weeks between Dupixent 300 mg Q2W (every two weeks) and placebo groups. The x-axis represents weeks from 0 to 48, and the y-axis shows LS mean change ± SE. Data points for Dupixent show a decrease below zero over 24 weeks and partial recovery in the post-treatment period (weeks 24 to 48), while placebo data remain near zero throughout.*

FDA Label Image

Dupixent 11c

Kaplan-Meier plot showing the probability of an event over 52 weeks comparing DUPIXENT 300 mg administered every two weeks (Q2W) with placebo administered every two weeks. The y-axis represents the probability of the event in percentage, and the x-axis shows time in weeks. A table below the graph displays the number of patients at risk at various time points for both groups.*

FDA Label Image

Figure (Dupixent 12)

An instructional diagram showing a syringe before and after use. The pre-use syringe includes labeled parts: plunger rod, finger grip, label, viewing window, syringe body, needle, and needle cap. The post-use syringe image shows the plunger rod pushed down with the needle exposed and a needle shield surrounding the needle.*

FDA Label Image

Dupixent 120

FDA Label Image

Dupixent 121

FDA Label Image

Dupixent 122

An instructional illustration showing the use of the Dupixent prefilled syringe for subcutaneous injection. It depicts a hand holding the syringe positioned near the thigh, with an arrow indicating the direction of injection.*

FDA Label Image

Dupixent 123

FDA Label Image

Dupixent 124

FDA Label Image

Dupixent 125

An instructional illustration showing a hand disposing of a syringe with a needle cap into a red sharps disposal container. The syringe and needle cap are clearly labeled, emphasizing proper disposal method for Dupixent injection materials.*

FDA Label Image

Dupixent 126

Dupixent (dupilumab) Injection carton for 300 mg/2 mL strength. The package contains 2 single-dose pre-filled syringes with needle shield for subcutaneous use only. Label shows storage instructions requiring refrigeration at 36°F to 46°F (2°C to 8°C) and warns against freezing and exposure to heat or direct sunlight. Manufactured by Sanofi Genzyme and Regeneron, labeled Rx Only. Includes barcode and space for serialization and distribution information.*

FDA Label Image

Dupixent 127

Dupixent (dupilumab) Injection 200 mg/1.14 mL single-dose pre-filled syringes with needle shield carton. The packaging is teal with white and orange details, indicating the strength 200 mg/1.14 mL (175 mg/mL). It specifies for subcutaneous use only and contains 2 pre-filled syringes. Labeler names Sanofi Genzyme and Regeneron are shown. Storage instructions and handling warnings are included on the carton.*

FDA Label Image

Dupixent 128

Packaging label for Dupixent 300 mg/2 mL (150 mg/mL) injection in a single-dose pre-filled pen. The carton contains 2 pre-filled pens. Labeler is Sanofi-Aventis U.S. LLC. Storage instructions advise refrigeration at 36° to 46°F (2° to 8°C), avoiding freezing, heat, and direct sunlight. Includes a barcode and safety warnings.*

FDA Label Image

Dupixent 129

Dupixent 200 mg/1.14 mL (175 mg/mL) injection single-dose pre-filled pen carton label. The label shows that the carton contains 2 single-dose pre-filled pens of dupilumab for subcutaneous use. It includes storage instructions, dosage form, and manufacturer names Sanofi Genzyme and Regeneron. The design features orange and green arrow graphics, with detailed handling and safety information.*

FDA Label Image

Figure (Dupixent 13)

FDA Label Image

Dupixent 130

Packaging label for Dupixent (dupilumab) Injection 100 mg/0.67 mL by Sanofi Genzyme and Regeneron. The carton contains 2 single-dose pre-filled syringes with needle shields. The label includes storage instructions to keep refrigerated and directions to see the package insert for dosage information. The design features green and teal colors with QR code and barcodes.*

FDA Label Image

Figure (Dupixent 14)

An instructional illustration showing a hand holding the Dupixent prefilled syringe inside an open cardboard box. The box contains foil pouches or packaging slots for organizing the medication components.*

FDA Label Image

Figure (Dupixent 15)

An instructional illustration showing the contents included with the Dupixent pre-filled syringe package: one pre-filled syringe, one alcohol wipe, one cotton ball or gauze, and one sharps disposal container.*

FDA Label Image

Figure (Dupixent 16)

Illustration showing the location of the expiration date label on a Dupixent prefilled syringe, highlighting where to find the lot number and expiration date information on the device.*

FDA Label Image

Figure (Dupixent 17)

An instructional diagram showing the Dupixent prefilled syringe with a focus on the viewing window. The image demonstrates how to hold the syringe to observe the label through the viewing window. Dupixent is available in strengths of 200 mg/1.14 mL and 300 mg/2 mL, labeled by Sanofi-Aventis U.S. LLC.*

FDA Label Image

Figure (Dupixent 18)

An instructional illustration showing an injection syringe with a timer set to 45 minutes, likely indicating a recommended wait or procedure time related to the use of Dupixent injectable product.*

FDA Label Image

Principal Display Panel (300 mg/2 mL Syringe Carton)

Illustration showing recommended injection sites for Dupixent. Light blue areas on the abdomen and thighs indicate sites for self-injection or caregiver administration. Dark blue areas on the upper arms indicate sites for injection by caregiver only.*

FDA Label Image

Principal Display Panel (300 mg/2 mL Syringe Carton)

An instructional illustration showing a person's hand applying a small rectangular patch to the skin on the lower abdomen, near the waistline. The image suggests the procedure of placing a transdermal or topical patch.*

FDA Label Image

Dupixent 21

An instructional illustration showing hands preparing a syringe injection device, likely related to Dupixent. The image demonstrates holding the syringe with one hand and removing or adjusting a component with the other, indicated by bidirectional arrows to show motion.*

FDA Label Image

Dupixent 22

An instructional illustration showing a person pinching the skin on the abdomen with their fingers, likely demonstrating how to prepare the injection site for administering Dupixent by subcutaneous injection.*

FDA Label Image

Dupixent 23

An instructional diagram showing the proper technique for administering an injection at a 45-degree angle into the skin. The illustration depicts a hand inserting a syringe into the skin, suggesting the positioning and angle for the injection.*

FDA Label Image

Dupixent 24

An instructional illustration showing the administration of a Dupixent injection using a prefilled syringe or auto-injector device. It depicts a hand holding the device positioned to inject into the abdominal area, demonstrating proper injection technique.*

FDA Label Image

Dupixent 25

An instructional illustration showing a hand holding a prefilled syringe or injector pen near a person’s abdomen, indicating the step of preparing for an injection by positioning the device against the skin. The image uses arrow and hand placement to demonstrate the technique.*

FDA Label Image

Dupixent 26

Instructional illustration showing a hand placing a syringe labeled 'Syringe' into a sharps disposal container. The container is marked with 'Sharps Disposal Container' and the lid has a labeled area for 'Needle Cap.' It demonstrates safe disposal of used syringes.*

FDA Label Image

Dupixent 27

An instructional diagram showing the Dupixent syringe before and after use. The 'Before Use' side labels the plunger rod, finger grip, viewing window, syringe body, needle, and needle cap. The 'After Use' side labels the plunger rod, finger grip, needle, and needle shield, depicting the syringe with the plunger fully depressed and the needle shield engaged.*

FDA Label Image

Dupixent 28

FDA Label Image

Dupixent 29

An instructional illustration showing a hand holding a Dupixent prefilled syringe inside an open box, displaying the syringe and the organized compartments within the packaging.*

FDA Label Image

Dupixent 30

An instructional illustration related to Dupixent pre-filled syringe, showing the required items for administration: 1 alcohol wipe, 1 cotton ball or gauze, and a sharps disposal container. The image includes simple icons representing each item for clarity.*

FDA Label Image

Dupixent 31

An instructional diagram showing how to locate the expiration date on the Dupixent prefilled syringe. The image highlights the side of the syringe barrel, indicating where the lot number and expiration date are printed on the label.*

FDA Label Image

Dupixent 32

An instructional diagram of a Dupixent prefilled syringe showing a viewing window that displays the lot number and expiration date. The syringe is depicted with a label indicating where to check these details before use.*

FDA Label Image

Dupixent 33

An instructional illustration depicting a syringe with a plunger and needle cap. Next to the syringe is a clock graphic indicating a 30-minute wait time, suggesting a post-injection waiting period or preparation time.*

FDA Label Image

Dupixent 34

An illustration showing recommended injection sites on a human body for Dupixent. Blue areas indicate sites for self-injection or injection by a caregiver, including the front thighs and abdomen. Dark blue areas on the upper arms indicate injection sites by a caregiver only.*

FDA Label Image

Dupixent 35

Instructional illustration showing a hand applying a small adhesive patch to the lower abdominal area, potentially demonstrating part of the application process for the Dupixent injection or related product use guidance.*

FDA Label Image

Dupixent 36

An instructional illustration showing a pair of hands demonstrating how to remove the cap from a syringe by pulling it straight off. The image focuses on the proper handling technique before administration.*

FDA Label Image

Dupixent 37

An instructional illustration showing a hand pinching the skin on the lower abdomen, demonstrating the proper site for injection, associated with Dupixent (dupilumab) administration.*

FDA Label Image

Dupixent 38

An instructional illustration showing a hand holding a Dupixent autoinjector at a 45-degree angle to the skin, with an arrow indicating the direction to press down for injection. The image visually demonstrates the correct angle and motion for administering the subcutaneous injection with the autoinjector.*

FDA Label Image

Dupixent 39

An instructional illustration showing a person administering an injection with a syringe into the abdominal area, highlighting the injection technique with a downward arrow indicating pressing the syringe into the skin.*

FDA Label Image

Dupixent 40

An illustration showing a hand holding a Dupixent prefilled syringe with the needle cap being removed by pulling it straight off, positioned above the other hand preparing for injection. The image demonstrates the correct step for needle cap removal prior to administration.*

FDA Label Image

Dupixent 41

An instructional illustration showing a hand disposing of a syringe by placing the needle cap into a red sharps disposal container. The diagram labels the syringe, needle cap, and the sharps disposal container.*

FDA Label Image

Dupixent 42

Illustration showing the Dupixent 300 mg/2 mL prefilled syringe before and after injection. The left image displays the green cap, medicine window, and label. The right image shows the syringe with the green cap removed and a yellow needle cover visible, indicating injection completion with a yellow window.*

FDA Label Image

Dupixent 43

Instructional diagram showing items recommended for use with the DUPIXENT pre-filled pen, including one alcohol wipe, one cotton ball or gauze, and a sharps disposal container. A note indicates these items are not included in the carton.*

FDA Label Image

Dupixent 44

An instructional illustration showing a Dupixent prefilled syringe labeled 300 mg/2 mL by Sanofi-Aventis U.S. LLC. The image highlights the syringe window with a yellow indicator and a red X mark, indicating a caution or error related to the window display.*

FDA Label Image

Dupixent 45

Packaging label of Dupixent 300 mg/2 mL prefilled syringe by Sanofi-Aventis U.S. LLC. The label shows the product name and strength prominently on a white background with green accents, including an image of the syringe. Text above instructs to 'Check the Medicine and Dose.'*

FDA Label Image

Dupixent 46

Dupixent 300 mg/2 mL single-dose prefilled syringe packaging label from Sanofi-Aventis U.S. LLC. The label displays the product name, strength, and dosage form along with usage instructions depicted in icons showing syringe handling steps. The background is predominantly white with colored sections and text for clarity.*

FDA Label Image

Dupixent 47

An instructional illustration showing a Dupixent prefilled syringe with a zoomed-in view of the expiration date area on the syringe barrel, indicating where to check for the expiration date.*

FDA Label Image

Dupixent 48

Dupixent 200 mg/1.14 mL single-dose prefilled syringe packaging label by Sanofi-Aventis U.S. LLC. The label includes the product name, strength, and dosage form with a simple design featuring blue and yellow accent colors on a white background.*

FDA Label Image

Dupixent 49

An instructional illustration showing a labeled 'Check Window' feature with a green check mark. The graphic highlights the importance of inspecting a specific window area, likely on a medication device, as part of its usage instructions.*

FDA Label Image

Dupixent 50

Dupixent 300 mg/2 mL, a single-dose prefilled syringe for injection, displayed with a clear plastic cap covering the needle. The syringe is marked with calibrated dosing lines and printed labeling indicating the product name, strength, and manufacturer, Sanofi-Aventis U.S. LLC.*

FDA Label Image

Dupixent 51

Illustration of a clock face showing a 45-minute interval, with a portion of the clock shaded to indicate the elapsed time. The text '45 minutes' is displayed prominently in the center of the clock.*

FDA Label Image

Dupixent 52

An illustration showing hands being washed under a running water faucet, depicting proper handwashing technique.*

FDA Label Image

Dupixent 53

Dupixent 300 mg/2 mL single-dose prefilled syringe packaging label by Sanofi-Aventis U.S. LLC. The label includes the brand name Dupixent, the strength 300 mg/2 mL, and features a colored design with orange and teal elements. Product and manufacturer information is presented clearly on the packaging.*

FDA Label Image

Dupixent 54

Dupixent 200 mg/1.14 mL single-dose prefilled syringe packaging label by Sanofi-Aventis U.S. LLC. The label highlights the brand name, dose strength, and prefilled syringe dosage form. It includes storage instructions, administration details, and barcodes on the packaging.*

FDA Label Image

Dupixent 55

Illustration showing recommended injection sites for Dupixent self-injection and caregiver injection. Self-injection sites include the abdomen (away from the navel) and front thighs. Caregiver injection sites include the outer upper arm, abdomen, and front thighs, highlighted in blue on body diagrams.*

FDA Label Image

Dupixent 56

Dupixent 200 mg/1.14 mL single-dose prefilled syringe carton label showing brand name, strength, dosage form, and manufacturer Sanofi-Aventis U.S. LLC. The label is white with purple and orange accents, including identification elements such as barcode and drug information.*

FDA Label Image

Dupixent 57

An instructional illustration showing a hand holding a small rectangular packet or patch positioned above an area of skin on the upper arm, indicating application of a product to the skin.*

FDA Label Image

Dupixent 58

Dupixent 300 mg/2 mL single-dose prefilled syringe label from Sanofi-Aventis U.S. LLC. The label clearly shows the brand name Dupixent, strength, dosage form as a prefilled syringe, and labeler information. It includes graphical elements and caution statements typical for injectable drug products.*

FDA Label Image

Dupixent 59

An instructional diagram showing how to remove the green cap from a Dupixent prefilled syringe. It highlights pulling the green cap straight off and warns not to touch the needle inside or remove the yellow safety cover. The syringe is labeled with the partial name 'DUPIXE.'*

FDA Label Image

Dupixent 60

An instructional illustration showing a hand holding a Dupixent autoinjector device at a 90-degree angle against a surface. The image highlights the autoinjector's window, indicating where to look during use. The diagram demonstrates correct positioning for administration.*

FDA Label Image

Dupixent 61

An instructional diagram showing how to use a Dupixent injection device. It illustrates the steps: pressing for the first click, watching the window turn yellow after the second click, and counting steadily up to five seconds while pressing to ensure proper injection.*

FDA Label Image

Dupixent 62

Dupixent 200 mg/1.14 mL subcutaneous injection single-dose pre-filled syringe carton label. The label prominently displays the product name, strength, dosage form, and pre-filled syringe illustration. Labeler is Sanofi-Aventis U.S. LLC. The packaging also includes a lot number/date section and needle safety descriptions.*

FDA Label Image

Dupixent 63

Dupixent 200 mg/1.14 mL injectable solution vial label, showing the product name, strength, dosage form as a single-dose vial, and the labeler Sanofi-Aventis U.S. LLC. The label features dosage and packaging details with distinctive brand and regulatory text.*

FDA Label Image

Dupixent 64

An instructional illustration showing a hand holding a Dupixent injection pen. The pen is positioned vertically above the injection site with an orange upward arrow indicating it is being lifted away after use.*

FDA Label Image

Dupixent 65

Dupixent 200 mg/1.14 mL single-dose vial packaging label from Sanofi-Aventis U.S. LLC. The label displays the product name, strength, and dosage form prominently along with usage instructions and safety warnings on the vial label.*

FDA Label Image

Dupixent 66

Dupixent 200 mg/1.14 mL and 300 mg/2 mL prefilled syringes by Sanofi-Aventis U.S. LLC. The image shows two individual glass syringes with clear barrels, needle caps, and black plungers. Each syringe is labeled with dosage and brand information clearly visible on the barrel.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.